Companies › Sparrow Pharmaceuticals
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Genitourinary, Metabolic and endocrine; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| clofutriben 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) inhibitor | HSD11B1 | Phase 2 | Type 2 Diabetes; Moderate Renal Impairment | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07227922 | clofutriben | Phase 1 | Moderate Renal Impairment | Genitourinary | Apr 2026 |
| NCT07296484 | clofutriben | Phase 2 | Type 2 Diabetes | Metabolic and endocrine | Dec 2027 |
Vifor Pharma Maze Therapeutics Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical Housey Healthcare ULC
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.